Diabetic Macular Edema Treated With Ozurdex (DMEO)

Completed · Phase 2

Conditions studied: Diabetic Macular Edema

In brief

To measure various pro-permeability factors in the aqueous humor of patients with persistent/recurrent diabetic macular edema

Key facts

Study ID

NCT01951066

Run by

Johns Hopkins University

People needed

20

Starts

2013-10-01

Expected to finish

2015-12-01

Last updated by the study team

2016-09-29

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• • Signed informed consent and authorization of use and disclosure of protected health information
• Age more than or equal to 18 years
• Diagnosis of diabetic macular edema
• Intraretinal or subretinal fluid in the macula determined by Spectralis OCT
• Best corrected visual acuity score in the study eye of 20/30 to 20/400 inclusive (Snellen equivalents using the ETDRS protocol at a distance of 4 meters)
• In the opinion of the investigator, decreased vision in the study eye is due to foveal thickening from DME and not from other obvious causes of decreased vision
• Persistent or recurrent edema despite prolonged treatment with an anti-VEFG agent

You may not qualify if…

• • Scatter laser photocoagulation or macular photocoagulation within 3 months of study entry in the study eye
• Intraocular surgery in the study eye within 3 months of study entry
• Use of intraocular or periocular injection of steroids in the study eye (e.g., triamcinolone) within 4 months of study entry
• Previous use of an anti-VEGF drug within 1 month of study entry
• Yttrium-Aluminum-Garnet (YAG) laser capsulotomy within 1 month of study entry
• Any condition that the investigator believes would pose a significant hazard to the subject if investigational therapy were initiated.
• Inability to comply with study or follow up procedures
• History of glaucoma. (Patients who have undergone filtration surgery may be included)
• Patients with active or suspected ocular or periocular infection, including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.
• Aphakic eyes with rupture of the posterior lens capsule.
• Eyes with ACIOL and rupture of the posterior lens capsule.
• Patients with hypersensitivity to dexamethasone or to any other components of the product

Where it is running

• Wilmer Eye Institute — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.